RESUMO
Filoviruses, mainly consisting of Ebola viruses (EBOV) and Marburg viruses (MARV), are enveloped negative-strand RNA viruses which can infect humans to cause severe hemorrhagic fevers and outbreaks with high mortality rates. The filovirus infection is mediated by the interaction of viral envelope glycoprotein (GP) and the human endosomal receptor Niemann-Pick C1 (NPC1). Blocking this interaction will prevent the infection. Therefore, we utilized an In silico screening approach to conduct virtual compound screening against the NPC1 receptor-binding site (RBS). Twenty-six top-hit compounds were purchased and evaluated by in vitro cell based inhibition assays against pseudotyped or replication-competent filoviruses. Two classes (A and U) of compounds were identified to have potent inhibitory activity against both Ebola and Marburg viruses. The IC50 values are in the lower level of micromolar concentrations. One compound (compd-A) was found to have a sub-micromolar IC50 value (0.86 µM) against pseudotyped Marburg virus. The cytotoxicity assay (MTT) indicates that compd-A has a moderate cytotoxicity level but the compd-U has much less toxicity and the CC50 value was about 100 µM. Structure-activity relationship (SAR) study has found some analogs of compd-A and -U have reduced the toxicity and enhanced the inhibitory activity. In conclusion, this work has identified several qualified lead-compounds for further drug development against filovirus infection.
Assuntos
Antivirais/farmacologia , Ebolavirus/efeitos dos fármacos , Infecções por Filoviridae/virologia , Marburgvirus/efeitos dos fármacos , Proteína C1 de Niemann-Pick/metabolismo , Proteínas do Envelope Viral/metabolismo , Internalização do Vírus/efeitos dos fármacos , Antivirais/química , Sítios de Ligação , Sobrevivência Celular , Descoberta de Drogas , Ebolavirus/fisiologia , Infecções por Filoviridae/tratamento farmacológico , Células HeLa , Interações entre Hospedeiro e Microrganismos/efeitos dos fármacos , Humanos , Concentração Inibidora 50 , Marburgvirus/fisiologia , Simulação de Acoplamento Molecular , Proteína C1 de Niemann-Pick/química , Ligação Proteica , Receptores Virais/química , Receptores Virais/metabolismoRESUMO
Ebolaviruses and marburgviruses, members of the family Filoviridae, are known to cause fatal diseases often associated with hemorrhagic fever. Recent outbreaks of Ebola virus disease in West African countries and the Democratic Republic of the Congo have made clear the urgent need for the development of therapeutics and vaccines against filoviruses. Using replication-incompetent vesicular stomatitis virus (VSV) pseudotyped with the Ebola virus (EBOV) envelope glycoprotein (GP), we screened a chemical compound library to obtain new drug candidates that inhibit filoviral entry into target cells. We discovered a biaryl sulfonamide derivative that suppressed in vitro infection mediated by GPs derived from all known human-pathogenic filoviruses. To determine the inhibitory mechanism of the compound, we monitored each entry step (attachment, internalization, and membrane fusion) using lipophilic tracer-labeled ebolavirus-like particles and found that the compound efficiently blocked fusion between the viral envelope and the endosomal membrane during cellular entry. However, the compound did not block the interaction of GP with the Niemann-Pick C1 protein, which is believed to be the receptor of filoviruses. Using replication-competent VSVs pseudotyped with EBOV GP, we selected escape mutants and identified two EBOV GP amino acid residues (positions 47 and 66) important for the interaction with this compound. Interestingly, these amino acid residues were located at the base region of the GP trimer, suggesting that the compound might interfere with the GP conformational change required for membrane fusion. These results suggest that this biaryl sulfonamide derivative is a novel fusion inhibitor and a possible drug candidate for the development of a pan-filovirus therapeutic.
Assuntos
Filoviridae/efeitos dos fármacos , Sulfonamidas/química , Sulfonamidas/farmacologia , Internalização do Vírus/efeitos dos fármacos , Animais , Chlorocebus aethiops , Descoberta de Drogas , Ebolavirus/efeitos dos fármacos , Filoviridae/classificação , Infecções por Filoviridae/tratamento farmacológico , Infecções por Filoviridae/virologia , Células HEK293 , Doença pelo Vírus Ebola/tratamento farmacológico , Humanos , Doença do Vírus de Marburg/tratamento farmacológico , Marburgvirus/efeitos dos fármacos , Receptores Virais/metabolismo , Células VeroRESUMO
The filovirus family includes some of the deadliest viruses known, including Ebola virus and Marburg virus. These viruses cause periodic outbreaks of severe disease that can be spread from person to person, making the filoviruses important public health threats. There remains a need for approved drugs that target all or most members of this virus family. Small molecule inhibitors that target conserved functions hold promise as pan-filovirus therapeutics. To date, compounds that effectively target virus entry, genome replication, gene expression, and virus egress have been described. The most advanced inhibitors are nucleoside analogs that target viral RNA synthesis reactions.
Assuntos
Antivirais/farmacologia , Desenvolvimento de Medicamentos , Ebolavirus/efeitos dos fármacos , Filoviridae/efeitos dos fármacos , Bibliotecas de Moléculas Pequenas/farmacologia , Animais , Antivirais/química , Antivirais/isolamento & purificação , Ensaios Clínicos como Assunto , Infecções por Filoviridae/tratamento farmacológico , Doença pelo Vírus Ebola/tratamento farmacológico , Humanos , Internalização do Vírus/efeitos dos fármacos , Liberação de Vírus/efeitos dos fármacosRESUMO
The 2014 Ebolavirus outbreak in West Africa highlighted the need for vaccines and therapeutics to prevent and treat filovirus infections. A well-characterized small animal model that is susceptible to wild-type filoviruses would facilitate the screening of anti-filovirus agents. To that end, we characterized knockout mice lacking α/ß and γ interferon receptors (IFNAGR KO) as a model for wild-type filovirus infection. Intraperitoneal challenge of IFNAGR KO mice with several known human pathogenic species from the genus Ebolavirus and Marburgvirus, except Bundibugyo ebolavirus and Taï Forest ebolavirus, caused variable mortality rate. Further characterization of the prototype Ebola virus Kikwit isolate infection in this KO mouse model showed 100% lethality down to a dilution equivalent to 1.0 × 10-1 pfu with all deaths occurring between 7 and 9 days post-challenge. Viral RNA was detectable in serum after challenge with 1.0 × 10² pfu as early as one day after infection. Changes in hematology and serum chemistry became pronounced as the disease progressed and mirrored the histological changes in the spleen and liver that were also consistent with those described for patients with Ebola virus disease. In a proof-of-principle study, treatment of Ebola virus infected IFNAGR KO mice with favipiravir resulted in 83% protection. Taken together, the data suggest that IFNAGR KO mice may be a useful model for early screening of anti-filovirus medical countermeasures.
Assuntos
Amidas/uso terapêutico , Antivirais/uso terapêutico , Infecções por Filoviridae/tratamento farmacológico , Pirazinas/uso terapêutico , Receptores de Interferon/genética , Animais , Modelos Animais de Doenças , Ebolavirus , Feminino , Filoviridae , Técnicas de Inativação de Genes , Doença pelo Vírus Ebola/tratamento farmacológico , Fígado/patologia , Masculino , Doença do Vírus de Marburg/tratamento farmacológico , Marburgvirus , Camundongos , Camundongos Knockout , Estudo de Prova de Conceito , RNA Viral/sangue , Receptores de Interferon/imunologia , Baço/patologia , VirulênciaRESUMO
The development of novel therapeutics and vaccines to treat or prevent disease caused by filoviruses, such as Ebola and Marburg viruses, depends on the availability of animal models that faithfully recapitulate clinical hallmarks of disease as it is observed in humans. In particular, small animal models (such as mice and guinea pigs) are historically and frequently used for the primary evaluation of antiviral countermeasures, prior to testing in nonhuman primates, which represent the gold-standard filovirus animal model. In the past several years, however, the filovirus field has witnessed the continued refinement of the mouse and guinea pig models of disease, as well as the introduction of the hamster and ferret models. We now have small animal models for most human-pathogenic filoviruses, many of which are susceptible to wild type virus and demonstrate key features of disease, including robust virus replication, coagulopathy, and immune system dysfunction. Although none of these small animal model systems perfectly recapitulates Ebola virus disease or Marburg virus disease on its own, collectively they offer a nearly complete set of tools in which to carry out the preclinical development of novel antiviral drugs.
Assuntos
Modelos Animais de Doenças , Infecções por Filoviridae/tratamento farmacológico , Infecções por Filoviridae/prevenção & controle , Filoviridae/patogenicidade , Animais , Cricetinae , Furões , Filoviridae/efeitos dos fármacos , Cobaias , Doença pelo Vírus Ebola/tratamento farmacológico , Doença pelo Vírus Ebola/prevenção & controle , Humanos , Doença do Vírus de Marburg/tratamento farmacológico , Doença do Vírus de Marburg/prevenção & controle , Camundongos , Vacinas ViraisRESUMO
INTRODUCTION: During the 2014-2016 Ebolavirus (EBOV) outbreak, several candidate therapeutics were used in EBOV-infected patients in clinical trials and under expanded access for emergency use. This review will focus briefly on medications used during the outbreak. We will discuss current therapeutic candidates and their status and will then turn to a related and essential topic: supportive care and the standard of care for filovirus infected patients. Potential benefits and pitfalls of combination therapies for filoviruses will be discussed. Areas covered: Clinical trials of therapeutics targeting EBOV; clinical usage of therapeutics during recent EBOV outbreak; potential need for combination therapy; role of supportive care in treatment of Ebola virus disease (EVD). Expert commentary: In the absence of another large scale EBOV outbreak, the path to therapeutic product licensure in the United States of America (USA) would need to be via the FDA Animal Rule. However, human data may be needed to supplement animal data. The future of filovirus therapeutics may therefore benefit by establishing the ability to implement clinical trials in an outbreak setting in a timely fashion. Supportive care guidelines for filovirus infection should be defined and established as standard of care for treatment of EVD.
Assuntos
Antivirais/uso terapêutico , Surtos de Doenças , Doença pelo Vírus Ebola/tratamento farmacológico , Animais , Antivirais/administração & dosagem , Aprovação de Drogas , Desenho de Fármacos , Quimioterapia Combinada , Ebolavirus/efeitos dos fármacos , Ebolavirus/isolamento & purificação , Filoviridae/efeitos dos fármacos , Filoviridae/isolamento & purificação , Infecções por Filoviridae/tratamento farmacológico , Infecções por Filoviridae/epidemiologia , Doença pelo Vírus Ebola/epidemiologia , HumanosRESUMO
As observed during the 2013-2016 Ebola virus disease epidemic, containment of filovirus outbreaks is challenging and made more difficult by the lack of approved vaccine or therapeutic options. Marburg and Ravn viruses are highly virulent and cause severe and frequently lethal disease in humans. Monoclonal antibodies (mAbs) are a platform technology in wide use for autoimmune and oncology indications. Previously, we described human mAbs that can protect mice from lethal challenge with Marburg virus. We demonstrate that one of these mAbs, MR191-N, can confer a survival benefit of up to 100% to Marburg or Ravn virus-infected rhesus macaques when treatment is initiated up to 5 days post-inoculation. These findings extend the small but growing body of evidence that mAbs can impart therapeutic benefit during advanced stages of disease with highly virulent viruses and could be useful in epidemic settings.
Assuntos
Anticorpos Monoclonais/uso terapêutico , Infecções por Filoviridae/tratamento farmacológico , Filoviridae/fisiologia , Doença do Vírus de Marburg/tratamento farmacológico , Marburgvirus/fisiologia , Animais , Proteção Cruzada , Infecções por Filoviridae/virologia , Cobaias , Humanos , Macaca fascicularis , Macaca mulatta , Doença do Vírus de Marburg/virologia , Projetos PilotoRESUMO
Filoviruses are important pathogens that cause severe and often fatal hemorrhagic fever in humans, for which no approved vaccines and antiviral treatments are yet available. In an earlier article (Martin et al., Antiviral Research, 2016), we reviewed the role of the filovirus surface glycoprotein in replication and as a target for drugs and vaccines. In this review, we focus on recent findings on the filovirus replication machinery and how they could be used for the identification of new therapeutic targets and the development of new antiviral compounds. First, we summarize the recent structural and functional advances on the molecules involved in filovirus replication/transcription cycle, particularly the NP, VP30, VP35 proteins, and the "large" protein L, which harbors the RNA-dependent RNA polymerase (RdRp) and mRNA capping activities. These proteins are essential for viral mRNA synthesis and genome replication, and consequently they constitute attractive targets for drug design. We then describe how these insights into filovirus replication mechanisms and the structure/function characterization of the involved proteins have led to the development of new and innovative antiviral strategies that may help reduce the filovirus disease case fatality rate through post-exposure or prophylactic treatments.
Assuntos
Antivirais/farmacologia , Descoberta de Drogas , Filoviridae/efeitos dos fármacos , Filoviridae/fisiologia , Proteínas Virais/metabolismo , Replicação Viral , Antivirais/química , Antivirais/metabolismo , Antivirais/uso terapêutico , Desenho de Fármacos , Ebolavirus/química , Ebolavirus/efeitos dos fármacos , Ebolavirus/metabolismo , Infecções por Filoviridae/tratamento farmacológico , Marburgvirus/química , Marburgvirus/efeitos dos fármacos , Marburgvirus/metabolismo , RNA Polimerase Dependente de RNA/química , RNA Polimerase Dependente de RNA/metabolismo , Fatores de Transcrição/química , Fatores de Transcrição/metabolismo , Proteínas Virais/química , Proteínas Virais/genética , Proteínas Virais/isolamento & purificação , Proteínas Virais Reguladoras e Acessórias/química , Proteínas Virais Reguladoras e Acessórias/metabolismoRESUMO
This review focuses on the recent progress in our understanding of filovirus protein structure/function and its impact on antiviral research. Here we focus on the surface glycoprotein GP1,2 and its different roles in filovirus entry. We first describe the latest advances on the characterization of GP gene-overlapping proteins sGP, ssGP and Δ-peptide. Then, we compare filovirus surface GP1,2 proteins in terms of structure, synthesis and function. As they bear potential in drug-design, the discovery of small organic compounds inhibiting filovirus entry is a currently very active field. Although it is at an early stage, the development of antiviral drugs against Ebola and Marburg virus entry might prove essential to reduce outbreak-associated fatality rates through post-exposure treatment of both suspected and confirmed cases.
Assuntos
Antivirais , Descoberta de Drogas , Filoviridae/efeitos dos fármacos , Filoviridae/fisiologia , Glicoproteínas/metabolismo , Proteínas do Envelope Viral/metabolismo , Internalização do Vírus , Animais , Anticorpos Neutralizantes , Anticorpos Antivirais , Antivirais/química , Antivirais/metabolismo , Antivirais/uso terapêutico , Ebolavirus/química , Filoviridae/química , Filoviridae/patogenicidade , Infecções por Filoviridae/tratamento farmacológico , Infecções por Filoviridae/virologia , Glicoproteínas/antagonistas & inibidores , Glicoproteínas/química , Humanos , Marburgvirus/química , Camundongos , Proteínas do Envelope Viral/antagonistas & inibidores , Proteínas do Envelope Viral/químicaRESUMO
Viruses from the Filoviridae family, as many other virus families, require an acidic pH for successful infection and are therefore susceptible to the actions of 4-aminoquinolines, such as chloroquine. Although the mechanisms of action of chloroquine clearly indicate that it might inhibit filoviral infections, several clinical trials that attempted to use chloroquine in the treatment of other acute viral infections - including dengue and influenza A and B - caused by low pH-dependent viruses, have reported that chloroquine had no clinical efficacy, and these results demoted chloroquine from the potential treatments for other virus families requiring low pH for infectivity. The present review is aimed at investigating whether chloroquine could combat the present Ebola virus epidemic, and also at exploring the main reasons for the reported lack of efficacy. Literature was sourced from PubMed, Scopus, Google Scholar, reference list of articles and textbooks - Fields Virology (Volumes 1and 2), the cytokine handbook, Pharmacology in Medicine: Principles and Practice, and hydroxychloroquine and chloroquine retinopathy. The present analysis concludes that (1) chloroquine might find a place in the treatment of Ebola, either as a monotherapy or in combination therapies; (2) the ineffectiveness of chloroquine, or its analogue, hydroxychloroquine, at treating infections from low pH-dependent viruses is a result of the failure to attain and sustain a steady state concentration sufficient to increase and keep the pH of the acidic organelles to approximately neutral levels; (3) to successfully treat filoviral infections - or other viral infections that emerge or emerged from low pH-dependent viruses - a steady state chloroquine plasma concentration of at least 1 µg/mL(~3.125 µM/L) or a whole blood concentration of 16 µM/L must be achieved and be sustained until the patients' viraemia becomes undetectable. These concentrations, however, do not rule out the efficacy of other, higher, steady state concentrations - although such concentrations might be accompanied by severe adverse effects or toxicities. The feasibility of the conclusion in the preceding texts has recently been supported by a subsequent study that shows that amodiaquine, a derivative of CQ, is able to protect humans infected with Ebola from death.
Assuntos
Cloroquina/uso terapêutico , Infecções por Filoviridae/tratamento farmacológico , Filoviridae/patogenicidade , Cloroquina/farmacologia , Filoviridae/efeitos dos fármacos , Concentração de Íons de Hidrogênio , Imunomodulação/efeitos dos fármacos , Organelas/efeitos dos fármacos , Organelas/metabolismo , Tropismo/efeitos dos fármacosRESUMO
Filoviruses cause severe hemorrhagic fevers with case fatality rates of up to 90%, for which no antivirals are currently available. Their categorization as biosafety level 4 agents restricts work with infectious viruses to a few maximum containment laboratories worldwide, which constitutes a significant obstacle for the development of countermeasures. Reverse genetics facilitates the generation of recombinant filoviruses, including reporter-expressing viruses, which have been increasingly used for drug screening and development in recent years. Further, reverse-genetics based lifecycle modeling systems allow modeling of the filovirus lifecycle without the need for a maximum containment laboratory and have recently been optimized for use in high-throughput assays. The availability of these reverse genetics-based tools will significantly improve our ability to find novel antivirals against filoviruses.
Assuntos
Antivirais/farmacologia , Infecções por Filoviridae/tratamento farmacológico , Filoviridae/genética , Modelos Teóricos , Genética Reversa/métodos , Antivirais/uso terapêutico , Descoberta de Drogas , Avaliação Pré-Clínica de Medicamentos , Ebolavirus/efeitos dos fármacos , Ebolavirus/genética , Ebolavirus/fisiologia , Filoviridae/efeitos dos fármacos , Filoviridae/fisiologia , Genoma Viral , Humanos , Testes de Sensibilidade Microbiana , Replicação ViralRESUMO
INTRODUCTION: Ebolaviruses and marburgviruses cause severe and often lethal human hemorrhagic fevers. As no FDA-approved therapeutics are available for these infections, efforts to discover new therapeutics are important, especially because these pathogens are considered biothreats and emerging infectious diseases. All methods for discovering new therapeutics should be considered, including compound library screening in vitro against virus and in silico structure-based drug design, where possible, if sufficient biochemical and structural information is available. AREAS COVERED: This review covers the structure and function of filovirus proteins, as they have been reported to date, as well as some of the current antiviral screening approaches. The authors discuss key studies mapping small-molecule modulators that were found through library and in silico screens to potential sites on viral proteins or host proteins involved in virus trafficking and pathogenesis. A description of ebolavirus and marburgvirus diseases and available animal models is also presented. EXPERT OPINION: To discover novel therapeutics with potent efficacy using sophisticated computational methods, more high-resolution crystal structures of filovirus proteins and more details about the protein functions and host interaction will be required. Current compound screening efforts are finding active antiviral compounds, but an emphasis on discovery research to investigate protein structures and functions enabling in silico drug design would provide another avenue for finding antiviral molecules. Additionally, targeting of protein-protein interactions may be a future avenue for drug discovery since disrupting catalytic sites may not be possible for all proteins.
Assuntos
Infecções por Filoviridae/tratamento farmacológico , Proteínas Virais/fisiologia , Animais , Antivirais/farmacologia , Antivirais/uso terapêutico , Simulação por Computador , Desenho de Fármacos , Filoviridae , Infecções por Filoviridae/fisiopatologia , Humanos , Proteínas Virais/químicaRESUMO
Filoviruses (Ebola and Marburg viruses) cause severe hemorrhagic fever in humans and nonhuman primates. No effective prophylaxis or treatment for filovirus diseases is yet commercially available. Recent studies have advanced our knowledge of filovirus protein functions and interaction between viral and host factors in the replication cycle. Current findings on the ecology of filoviruses (i.e., natural infection of nonprimate animals and discovery of a new member of filoviruses in Europe) have also provided new insights into the epidemiology of Ebola and Marburg hemorrhagic fever. This article reviews the fundamental aspects of filovirus biology and the latest topics on filovirus research.
Assuntos
Filoviridae , Animais , Adesão Celular , Descoberta de Drogas , Filoviridae/classificação , Filoviridae/genética , Filoviridae/patogenicidade , Filoviridae/fisiologia , Infecções por Filoviridae/tratamento farmacológico , Infecções por Filoviridae/prevenção & controle , Infecções por Filoviridae/transmissão , Infecções por Filoviridae/virologia , Humanos , Terapia de Alvo Molecular , Proteínas Virais/fisiologia , Vírion , Replicação Viral/genéticaRESUMO
There exists an urgent need to develop licensed drugs and vaccines for the treatment or prevention of filovirus infections. FGI-103 is a low-molecular-weight compound that was discovered through an in vitro screening assay utilizing a variant of Zaire ebolavirus (ZEBOV) that expresses green fluorescent protein. In vitro analyses demonstrated that FGI-103 also exhibits antiviral activity against wild-type ZEBOV and Sudan ebolavirus, as well as Marburgvirus (MARV) strains Ci67 and Ravn. In vivo administration of FGI-103 as a single intraperitoneal dose of 10 mg/kg delivered 24 h after infection is sufficient to completely protect mice against a lethal challenge with a mouse-adapted strain of either ZEBOV or MARV-Ravn. In a murine model of ZEBOV infection, delivery of FGI-103 reduces viremia and the viral burden in kidney, liver, and spleen tissues and is associated with subdued and delayed proinflammatory cytokine responses and tissue pathology. Taken together, these results identify a promising antiviral therapeutic candidate for the treatment of filovirus infections.
Assuntos
Amidinas/farmacologia , Antivirais/farmacologia , Benzofuranos/farmacologia , Infecções por Filoviridae/tratamento farmacológico , Filoviridae/efeitos dos fármacos , Amidinas/química , Animais , Antivirais/química , Benzofuranos/química , Chlorocebus aethiops , Citocinas/metabolismo , Ebolavirus/efeitos dos fármacos , Ebolavirus/genética , Feminino , Filoviridae/genética , Infecções por Filoviridae/imunologia , Infecções por Filoviridae/patologia , Proteínas de Fluorescência Verde/genética , Doença pelo Vírus Ebola/tratamento farmacológico , Doença pelo Vírus Ebola/imunologia , Doença pelo Vírus Ebola/patologia , Células Hep G2 , Humanos , Rim/citologia , Fígado/patologia , Fígado/virologia , Masculino , Doença do Vírus de Marburg/tratamento farmacológico , Doença do Vírus de Marburg/imunologia , Doença do Vírus de Marburg/patologia , Marburgvirus/efeitos dos fármacos , Marburgvirus/genética , Camundongos , Camundongos Endogâmicos C57BL , Peso Molecular , Bibliotecas de Moléculas Pequenas , Células VeroRESUMO
OBJECTIVE: To develop consensus-based recommendations for measures to be taken by medical and public health professionals if hemorrhagic fever viruses (HFVs) are used as biological weapons against a civilian population. PARTICIPANTS: The Working Group on Civilian Biodefense included 26 representatives from academic medical centers, public health, military services, governmental agencies, and other emergency management institutions. EVIDENCE: MEDLINE was searched from January 1966 to January 2002. Retrieved references, relevant material published prior to 1966, and additional sources identified by participants were reviewed. CONSENSUS PROCESS: Three formal drafts of the statement that synthesized information obtained in the evidence-gathering process were reviewed by the working group. Each draft incorporated comments and judgments of the members. All members approved the final draft. CONCLUSIONS: Weapons disseminating a number of HFVs could cause an outbreak of an undifferentiated febrile illness 2 to 21 days later, associated with clinical manifestations that could include rash, hemorrhagic diathesis, and shock. The mode of transmission and clinical course would vary depending on the specific pathogen. Diagnosis may be delayed given clinicians' unfamiliarity with these diseases, heterogeneous clinical presentation within an infected cohort, and lack of widely available diagnostic tests. Initiation of ribavirin therapy in the early phases of illness may be useful in treatment of some of these viruses, although extensive experience is lacking. There are no licensed vaccines to treat the diseases caused by HFVs.
Assuntos
Infecções por Arenaviridae/prevenção & controle , Guerra Biológica , Bioterrorismo , Infecções por Bunyaviridae/prevenção & controle , Defesa Civil/normas , Infecções por Filoviridae/prevenção & controle , Infecções por Flavivirus/prevenção & controle , Febres Hemorrágicas Virais/prevenção & controle , Administração em Saúde Pública/normas , Prática de Saúde Pública/normas , Aerossóis , Antivirais/uso terapêutico , Arenaviridae/patogenicidade , Infecções por Arenaviridae/diagnóstico , Infecções por Arenaviridae/tratamento farmacológico , Infecções por Arenaviridae/epidemiologia , Infecções por Arenaviridae/transmissão , Bunyaviridae/patogenicidade , Infecções por Bunyaviridae/diagnóstico , Infecções por Bunyaviridae/tratamento farmacológico , Infecções por Bunyaviridae/epidemiologia , Infecções por Bunyaviridae/transmissão , Cadáver , Técnicas de Laboratório Clínico , Planejamento em Desastres/normas , Surtos de Doenças/prevenção & controle , Filoviridae/patogenicidade , Infecções por Filoviridae/diagnóstico , Infecções por Filoviridae/tratamento farmacológico , Infecções por Filoviridae/epidemiologia , Infecções por Filoviridae/transmissão , Flaviviridae/patogenicidade , Infecções por Flavivirus/diagnóstico , Infecções por Flavivirus/tratamento farmacológico , Infecções por Flavivirus/epidemiologia , Infecções por Flavivirus/transmissão , Febres Hemorrágicas Virais/diagnóstico , Febres Hemorrágicas Virais/tratamento farmacológico , Febres Hemorrágicas Virais/epidemiologia , Febres Hemorrágicas Virais/transmissão , Controle de Infecções , Pesquisa , Ribavirina/uso terapêutico , Estados Unidos , Vacinas ViraisAssuntos
Antivirais/uso terapêutico , Infecções por Filoviridae/tratamento farmacológico , Animais , Modelos Animais de Doenças , Filoviridae/classificação , Filoviridae/efeitos dos fármacos , Filoviridae/genética , Filoviridae/fisiologia , Infecções por Filoviridae/imunologia , Infecções por Filoviridae/fisiopatologia , Infecções por Filoviridae/virologia , Humanos , Pesquisa , Síndrome , Vírion , Replicação ViralRESUMO
Adult immunocompetent mice inoculated with Ebola (EBO) or Marburg (MBG) virus do not become ill. A suckling-mouse-passaged variant of EBO Zaire '76 ('mouse-adapted EBO-Z') causes rapidly lethal infection in adult mice after intraperitoneal (i.p.) inoculation, but does not cause apparent disease when inoculated subcutaneously (s.c.). A series of experiments showed that both forms of resistance to infection are mediated by the Type I interferon response. Mice lacking the cell-surface IFN-alpha/beta receptor died within a week after inoculation of EBO-Z '76, EBO Sudan, MBG Musoke or MBG Ravn, or after s.c. challenge with mouse-adapted EBO-Z. EBO Reston and EBO Ivory Coast did not cause illness, but immunized the mice against subsequent challenge with mouse-adapted EBO-Z. Normal adult mice treated with antibodies against murine IFN-alpha/beta could also be lethally infected with i.p.-inoculated EBO-Z '76 or EBO Sudan and with s.c.-inoculated mouse-adapted EBO-Z. Severe combined immunodeficient (SCID) mice became ill 3-4 weeks after inoculation with EBO-Z '76, EBO Sudan or MBG Ravn, but not the other viruses. Treatment with anti-IFN-alpha/beta antibodies markedly accelerated the course of EBO-Z '76 infection. Antibody treatment blocked the effect of a potent antiviral drug, 3-deazaneplanocin A, indicating that successful filovirus therapy may require the active participation of the Type I IFN response. Mice lacking an IFN-alpha/beta response resemble primates in their susceptibility to rapidly progressive, overwhelming filovirus infection. The outcome of filovirus transfer between animal species appears to be determined by interactions between the virus and the innate immune response.